Through our partnership with the Independent Beauty Association and our sponsorship of the Fiscal Note U.S. Policy Map, we equip beauty brands with real-time regulatory insights and expert support, helping them stay compliant with MoCRA and confidently navigate the U.S. market.
The year 2026 brings numerous regulatory deadlines affecting cosmetic product labelling across several territories, including the European Union, United Kingdom, Switzerland, Canada, and the United States.
With clear guidance from Obelis Group, Kogenebiotech Co., Ltd. achieved a smooth, confident, and fully compliant EU Class A IVD notification through transparent communication and precise guidance.
Luxe Assist Global Inc. partnered with Obelis Group to streamline compliance, refine labelling, and confidently achieve a smooth, delay-free UK market entry for their microneedle derma roller.
Obelis Group will participate as a Contributing Partner in the 10th ERPA Annual Summit 2026, a key European forum uniting regulators and industry experts to discuss evolving expectations in EU cosmetics compliance and the practical responsibilities of the Responsible Person.
Sandra Ferretti is Chief Compliance Officer and Board Member at Obelis Group, working daily at the heart of regulatory complexity. Beyond compliance, she is also a singer. In this interview, she reflects on how structure and creativity come together in her life and influence the way she leads.
The EU has unveiled a proposal to simplify the MDR and IVDR framework, introducing updates designed to ease compliance and support innovation. Here’s what’s changing and what manufacturers need to do next.
Obelis Group supported RF Medical Co., Ltd. with the efficient issuance of EU Free Sales Certificates, enabling compliant and timely medical device registrations in Jordan and Vietnam to support global market expansion.
Obelis Group supported RNDENT, a manufacturer of Class I dental medical devices, with a seamless MHRA registration update during account renewal, ensuring uninterrupted access to the UK market through efficient and compliant regulatory support.
EUDAMED becomes mandatory on 28 May 2026. Discover key deadlines for actor, device, and certificate registrations under MDR and IVDR, and how to prepare.